Eloralintide
Eli Lilly's Selective Amylin Receptor Agonist
Eloralintide (LY3841136) is not another GLP-1. It is Eli Lilly's investigational once-weekly selective amylin receptor agonist — a fundamentally different approach to weight loss that works through the body's amylin hormone signaling. Phase 2 results show up to 20% mean weight loss over 48 weeks, with the majority of that coming from fat mass. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Eloralintide?
Eloralintide (development code LY3841136) is Eli Lilly's investigational selective amylin receptor agonist. Unlike GLP-1 drugs such as Semaglutide (Wegovy/Ozempic) or dual agonists like Tirzepatide (Mounjaro/Zepbound), Eloralintide works through an entirely different hormonal pathway.
Amylin is a peptide hormone naturally co-secreted with insulin by the pancreatic beta-cells in response to food intake. It plays a central role in controlling how fast your stomach empties, suppressing post-meal glucagon release, and signaling fullness to the brain. By selectively targeting the amylin 1 receptor (AMY1R), Eloralintide amplifies these natural satiety signals to reduce calorie intake and promote significant weight loss.
This makes Eloralintide a distinct and complementary tool in the metabolic medicine landscape, potentially working alongside GLP-1 therapies rather than simply competing with them. Eli Lilly is already studying Eloralintide in combination with tirzepatide. Track your current protocol in Shotlee while this science evolves.
The Amylin Mechanism
Satiety Signaling
- • Activates amylin 1 receptors (AMY1R)
- • Signals fullness to the brain earlier
- • Reduces calorie intake naturally
- • Track appetite changes in Shotlee
Gastric & Glucagon Control
- • Slows gastric emptying rate
- • Inhibits post-meal glucagon secretion
- • Helps stabilize blood sugar levels
- • Log GI symptoms in Shotlee
Fat-Targeted Loss
- • 60-70% of weight loss is fat mass
- • Preserves lean muscle tissue
- • Improves body composition ratio
- • Monitor body composition in Shotlee
Why This Matters
Amylin-based weight loss is mechanistically distinct from GLP-1 therapies. This opens the door to combination approaches — Eli Lilly is already testing Eloralintide together with tirzepatide. Tracking your current protocol data in Shotlee positions you to compare outcomes if you ever transition to or add an amylin agonist.
Phase 2 Clinical Results (48 Weeks)
A 48-week, multicenter, double-blind, randomized, placebo-controlled Phase 2 trial investigated multiple Eloralintide doses in 263 adults with obesity or overweight and at least one weight-related comorbidity.
At the 9 mg dose, participants lost an average of 20% of their body weight over 48 weeks, compared to only -0.4% with placebo. Use Shotlee to track similar milestones.
More than half of participants on 9 mg achieved at least 20% total body weight reduction. Track whether you reach deep-responder territory in the Shotlee app.
The majority of weight lost was attributable to fat mass reduction, preserving lean body tissue — one of the strongest arguments for amylin-based therapy.
Eli Lilly plans to initiate Phase 3 trials for Eloralintide by end of 2025. An additional Phase 2 study is also ongoing, testing Eloralintide in combination with tirzepatide for obesity with Type 2 diabetes.
Side Effects
Most Common
- • Nausea (32.7% vs 13.5% placebo)
- • Fatigue
- • Mild GI symptoms
- • More prevalent at higher doses
- • Log all side effects in Shotlee
Tolerability
- • Generally well tolerated overall
- • Slower dose escalation reduces side effects
- • Low-dose arms (1-3 mg) similar to placebo
- • No major safety signals identified
- • Track symptom trends over time in Shotlee
Eloralintide vs Current Options
| Drug | Mechanism | Weight Loss | Company |
|---|---|---|---|
| Eloralintide | Selective Amylin Receptor Agonist | ~20% (Phase 2) | Eli Lilly |
| Retatrutide | GLP-1 + GIP + Glucagon | ~29% (Phase 3) | Eli Lilly |
| Zepbound/Mounjaro | GLP-1 + GIP | ~18-21% | Eli Lilly |
| Wegovy | GLP-1 only | ~15-17% | Novo Nordisk |
All listed medications can be tracked in the free Shotlee app. Build your baseline data now and compare how different drug classes — including amylin agonists — perform for your body over time.
Vital Protocol FAQs
Is Eloralintide a GLP-1 drug?
No. Eloralintide is a selective amylin receptor agonist, which is a fundamentally different drug class from GLP-1 medications. It works through the amylin hormone pathway rather than GLP-1 signaling. This distinction is important because it means Eloralintide could potentially be used in combination with GLP-1 drugs for enhanced results.
Can I get Eloralintide now?
No, Eloralintide is not yet approved or available outside of clinical trials. Phase 3 trials are expected to begin by end of 2025. In the meantime, use Shotlee to track your current FDA-approved protocol and build data you can reference later.
How does it compare to Semaglutide?
They target completely different receptors. Semaglutide is a GLP-1 agonist; Eloralintide is an amylin agonist. In Phase 2, Eloralintide at 9 mg showed about 20% weight loss, which is competitive with approved dual agonists. The key advantage may be in combination — the two drug classes could work synergistically. Compare your outcomes across medications in Shotlee.
Why should I start tracking now?
Having clean baseline data is invaluable. When amylin agonists like Eloralintide become available, you will be able to see exactly how your body responds compared to your previous GLP-1 protocol. Shotlee stores your entire history — doses, weight, symptoms, labs — so switching drug classes only means continuing your data story, not starting over.
Prepare for Better Protocol Outcomes
Track your protocol with Shotlee and make every decision from clean, visible data instead of guesswork. Whether you are on a GLP-1 or preparing for an amylin agonist like Eloralintide, your data matters.
🚀 Use Shotlee for Free